Immunoglobulines in the treatment of multiple sclerosis after failure or intolerability of licensed therapies – results of a retrospective multicentre observational study

The efficacy of IVIG in the treatment of patients with multiple sclerosis (MS) is still under discussion. Despite evidence from clinical trials and daily practice available data are seen as insufficient to license intravenous immunoglobulines for treatment of relapsing-remitting multiple sclerosis (RR-MS). However according to national and international consensus IVIG are proposed as second line therapy in case of intolerability or failure of licensed medications. Nevertheless, even under this condition, patients experience severe problems to get the chance to benefit of the well tolerated IVIG therapy. In this…